Systemic Lupus Erythematosus

Etiology and Clinical Context

SLE is a chronic relapsing systemic autoimmune disease with heterogeneous presentations. Genetic susceptibility, hormonal factors, ultraviolet exposure, and other environmental or immunologic triggers influence loss of immune tolerance. It is more common in women and may cause greater morbidity in populations affected by barriers to timely specialty care, organ surveillance, and effective therapy.

Positive autoantibodies alone do not describe the burden of disease. Some patients experience predominantly cutaneous and musculoskeletal disease; others develop nephritis, hematologic cytopenias, serositis, neuropsychiatric disease, or vascular complications.

Epidemiology and Risk Profile

Risk is shaped by biology as well as access to care. Delays in recognizing nephritis, obtaining specialist follow-up, or maintaining treatment can increase preventable organ damage. Assessment should include barriers to medication access, laboratory monitoring, and ongoing care.

Pathophysiology

Loss of tolerance and the interferon amplification loop

Inadequate clearance of apoptotic cellular material exposes nuclear antigens to the immune system. Plasmacytoid dendritic cells and nucleic-acid sensing pathways promote type I interferon production, supporting B-cell activation and autoantibody responses. Feed-forward inflammation can sustain disease activity long after the initiating trigger (Gelber et al., 2019).

Immune complexes and complement

Antinuclear antibodies bind nuclear antigens to form immune complexes that may lodge in glomeruli, vessel walls, skin, and other tissues. Classical complement activation recruits inflammatory cells; C3 and C4 may decline with consumption, particularly during some nephritis flares. Complement concentrations are imperfect and must be interpreted longitudinally with clinical findings.

More than type III hypersensitivity

SLE can produce type II antibody-mediated cytotoxicity, including autoimmune hemolytic anemia and some immune-mediated cytopenias, in addition to type III immune-complex injury. Antiphospholipid antibodies can promote thrombosis rather than simply inflammatory vessel deposition.

Why lupus nephritis matters

Glomerular immune deposits activate mesangial and endothelial inflammation, disrupt the filtration barrier, and produce proteinuria, hematuria, and reduced renal function. Biopsy distinguishes proliferative from membranous and other patterns, which carry different risks and treatment implications (Kidney Disease: Improving Global Outcomes [KDIGO] Lupus Nephritis Work Group, 2024).

A Multiorgan SLE Injury Cascade

The consequences of systemic autoimmunity depend on the tissue and effector pathway involved. Immune-complex deposition can injure glomeruli, whereas antibodies against blood cells may produce cytopenias and antiphospholipid antibodies may contribute to thrombosis. A patient can experience several mechanisms simultaneously, so new organ symptoms need their own differential.

Organ Injury: Clinical Pattern and Mechanism

Organ domain	Primary pathophysiology	Findings and consequences
Glomeruli	Immune-complex deposition, complement and inflammatory injury	Proteinuria, hematuria, casts, edema, hypertension or declining GFR
Blood cells	Autoantibody-mediated destruction, marrow/inflammatory effects, or other causes	Hemolytic anemia, leukopenia or thrombocytopenia; evaluate the mechanism of each cytopenia
Serosal surfaces	Inflammation of pleura or pericardium	Pleuritic chest pain, effusions, possible pericardial complications
Skin and joints	Photosensitive immune injury and usually nonerosive arthritis	Malar or other cutaneous lupus lesions, oral ulcers, synovitis and pain
Vascular system	Antiphospholipid antibody-related coagulation activation or accelerated atherosclerosis	Thrombotic events and heightened cardiovascular risk; not all vascular events are vasculitis
Nervous system	Heterogeneous inflammatory, vascular and other mechanisms	Seizures or neuropsychiatric changes require assessment for infection, medications and metabolic causes too

The renal manifestation is especially important because mild extrarenal symptoms can coexist with clinically significant glomerular disease. Biopsy distinguishes active inflammation that may respond to immune therapy from established chronic scarring, and classifies proliferative (typically III/IV) versus membranous (V) patterns with different management implications (Sammaritano et al., 2025).

Clinical Manifestations

Common features include fatigue, inflammatory arthralgia or arthritis, photosensitive rashes, oral or nasal ulcers, alopecia, Raynaud phenomenon, and serositis. Fever and fatigue can reflect inflammation but are not specific and should not be reflexively labeled as a flare. Arthritis is usually nonerosive, unlike typical rheumatoid arthritis.

Major systemic manifestations include glomerulonephritis, pleuritis, pericarditis, autoimmune hemolytic anemia, leukopenia, thrombocytopenia, seizures or other neuropsychiatric syndromes, and accelerated vascular risk. Infections can mimic active SLE and are particularly important when the patient is receiving immunosuppressive treatment.

Diagnostic Evaluation

ANA is an appropriate screening test when clinical suspicion is meaningful, but many people with positive ANA do not have SLE. The 2019 EULAR/ACR classification framework uses ANA at least 1:80 as an entry criterion and weighted clinical and immunologic features; these are classification criteria, not a shortcut to diagnosis (Aringer et al., 2019).

Assess anti-dsDNA and anti-Sm, C3/C4, CBC, kidney function, urinalysis with sediment, and urine protein quantification as indicated. Anti-dsDNA may track activity in some patients; anti-Sm is relatively specific but less sensitive. Complement trends are useful only as part of a broader assessment.

Evaluate antiphospholipid antibodies when relevant to thrombosis, pregnancy morbidity, or characteristic clinical context. Kidney biopsy is considered when proteinuria or kidney dysfunction raises concern for lupus nephritis, as biopsy class informs immunosuppressive intensity and prognosis.

Expected Findings and Diagnostic Interpretation

Investigation	Reason for testing	Important interpretation
ANA	Sensitive entry point when SLE is clinically suspected	Common in other conditions and sometimes healthy people; not diagnostic alone
Anti-dsDNA and anti-Sm	Provide more specific immunologic evidence	Anti-dsDNA may correlate with activity in some patients; normal or negative does not exclude all disease
C3 and C4	Can fall through classical complement pathway activation and consumption	Not a stand-alone flare measure; patterns vary by patient and organ
CBC, smear and hemolysis markers when indicated	Characterize cytopenias and distinguish hemolysis or other pathology	Anemia and low platelets do not prove immune cytotoxicity without evaluation
Urinalysis with sediment and urine protein/creatinine	Identify and quantify glomerular injury	Proteinuria can be present before marked creatinine elevation; serial values matter
Renal biopsy	Defines histologic class, activity/chronicity and mimics when nephritis is suspected	Serology cannot assign biopsy class or directly determine immunosuppressive intensity
Antiphospholipid antibody evaluation	Assesses relevant thrombotic or obstetric phenotype	Positive result alone is insufficient for APS; persistent positivity and clinical criteria matter

Classification Versus Diagnosis

The 2019 EULAR/ACR criteria are for classification rather than obligatory bedside diagnosis: positive ANA of at least 1:80 at any point is the entry criterion, and a total of at least 10 weighted points with at least one clinical feature is required after excluding more likely explanations. Within each domain, count only the highest-weighted criterion. Thrombocytopenia earns classification points only below 100,000/µL; mildly low platelets should still be evaluated on clinical grounds.

A classification score neither grades disease severity nor determines treatment intensity. Negative anti-dsDNA testing or normal complement also cannot replace organ-specific evaluation when renal, hematologic, or cardiopulmonary findings are concerning.

Differential Diagnosis

In suspected SLE, consider drug-induced lupus, viral or other systemic infections, RA or overlap connective tissue disease, immune-complex vasculitis and antiphospholipid syndrome as indicated by the presenting pattern. Active urinary sediment and renal dysfunction require differentiation from infection-related glomerulonephritis, ANCA-associated vasculitis, thrombotic microangiopathy and noninflammatory kidney disease. In the case of dyspnea, chest pain, anemia and thrombocytopenia, evaluate pulmonary embolism, serositis, pulmonary edema, infection and hemolysis rather than assuming that every abnormality reflects one lupus flare.

Diagnostic Limitations and Reassessment

Serial urine protein, sediment, blood pressure and kidney function are more actionable for renal monitoring than anti-dsDNA or complement alone. The 2024 ACR lupus nephritis guideline, published in 2025, recommends proteinuria screening at least every 6–12 months in SLE without known nephritis, with more frequent monitoring in active nephritis; proteinuria should be quantified at least every three months when a complete renal response has not been reached. Rising proteinuria or declining eGFR requires reassessment for active disease, scarring, infection, medication nephrotoxicity or another renal process (Sammaritano et al., 2025).

When the clinical picture changes

• New edema, hypertension, active urine sediment or renal dysfunction: quantify proteinuria and investigate nephritis promptly.
• New fever on immunosuppression: evaluate infection independently of serologic activity.
• Dyspnea, chest pain or new neurologic changes: assess urgent cardiopulmonary and vascular causes.
• Persistent proteinuria despite treatment: reconsider adherence, treatment toxicity, active inflammation and irreversible damage; specialist evaluation may require repeat biopsy.

Management and Mechanistic Rationale

Hydroxychloroquine is a foundational therapy for most patients because it modifies endosomal immune signaling and reduces flares and cumulative damage; dosing and retinal monitoring matter. Sun protection, cardiovascular risk modification, vaccination review, and surveillance are also components of long-term management.

Glucocorticoids can rapidly suppress inflammation but carry substantial cumulative toxicity; disease-modifying agents are used to minimize steroid exposure. Mycophenolate, azathioprine, cyclophosphamide, belimumab, calcineurin inhibitors, and other therapies may be appropriate based on the involved organ and risk profile. Renal regimens depend on biopsy findings and current nephritis guidelines. Not every lupus manifestation requires the same immunosuppressive approach.

Complications and Red Flags

Threats include proliferative lupus nephritis, thrombotic events associated with antiphospholipid antibodies, severe cytopenias, neuropsychiatric involvement, pulmonary hemorrhage, and cardiovascular disease. A patient with new proteinuria needs renal risk assessment even if musculoskeletal symptoms are mild.

Distinguish infection from flare in febrile immunosuppressed patients. Anti-dsDNA changes or low complement alone should not automatically trigger treatment escalation without clinical assessment and organ evaluation.

Clinical Reasoning Priorities

Correlate the mechanism with the affected compartment: immune complexes with glomerular injury, cytotoxic antibodies with selected blood-cell destruction, antiphospholipid antibodies with vascular thrombosis, and cytokine signaling with constitutional and tissue inflammation.

Follow disease activity using serial patient-centered organ measures rather than one biomarker. A normal CRP does not exclude clinically important SLE activity, while a markedly elevated CRP may warrant careful investigation for infection or serositis.

Applied Clinical Reasoning

Case: A 19-year-old woman has one month of progressive dyspnea, chest pain, and generalized edema (anasarca), with malar rash, alopecia, oral ulcers, knee arthralgia, and blood pressure 150/90 mmHg. Hemoglobin is 9.0 g/dL, platelets 116,000/µL, creatinine 2.68 mg/dL; urine shows 3+ protein and 3+ blood.

Initial assessment: Chest symptoms, hypertension, edema, and new kidney dysfunction require immediate cardiopulmonary and renal assessment. The rash suggests a systemic autoimmune process but does not establish the cause of dyspnea.

Working differential: The mucocutaneous and joint findings support possible SLE, while proteinuria, hematuria, and impaired filtration raise concern for glomerulonephritis. Anemia and thrombocytopenia warrant independent assessment for immune cytopenias, hemolysis, systemic inflammation, or thrombotic microangiopathy.

Investigation: Repeat the CBC, renal function, and electrolytes; obtain urine microscopy and a protein/creatinine ratio. ANA, anti-dsDNA, anti-Sm, and C3/C4 testing can support the autoimmune assessment, while chest symptoms require appropriate cardiopulmonary investigations. If hemolysis or thrombotic microangiopathy is suspected, assess the peripheral smear, LDH, haptoglobin, and bilirubin and obtain urgent specialist input. Renal biopsy may be needed to characterize glomerular injury and guide treatment.

Interpretation: The platelet count of 116,000/µL is abnormal but does not meet the 2019 EULAR/ACR thrombocytopenia classification threshold of <100,000/µL. Classification points should not delay assessment of potentially serious renal disease.

Management logic: Hydroxychloroquine is foundational for most patients with SLE, but this presentation calls for prompt renal and cardiopulmonary assessment and specialist-directed treatment. Suspected active lupus nephritis may require glucocorticoid-based induction with early steroid-sparing immunotherapy and kidney-protective care, tailored to biopsy findings. The lupus nephritis guideline addresses renal treatment; the separate 2025 ACR SLE treatment guideline primarily addresses nonrenal disease (Sammaritano et al., 2025, 2026).

High-Yield Distinctions

Finding	Mechanistic meaning	Practice implication
ANA positive without compatible manifestations	Sensitive autoimmune marker; poor specificity	Do not diagnose SLE from serology alone
Anti-dsDNA rise with proteinuria and low complement	Possible increased immune-complex disease activity	Assess nephritis urgently and quantify organ injury
Hemolytic anemia with positive direct antiglobulin test	Antibody-mediated red-cell destruction	Recognize a cytotoxic mechanism distinct from glomerular immune complexes

Related YourDNP Guides

• Back to Pathophysiology
• Musculoskeletal and Rheumatic Foundations
• Immune Complex Vasculitis
• Sjögren Disease

---

---

References

Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey-Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., Jayne, D., Cervera, R., Costedoat-Chalumeau, N., Diamond, B., Gladman, D. D., Hahn, B., Hiepe, F., Jacobsen, S., Khanna, D., . . . Johnson, S. R. (2019). 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis & Rheumatology, 71(9), 1400–1412. https://doi.org/10.1002/art.40930

Gelber, A. C., Levine, S. M., & Darrah, E. (2019). Inflammatory rheumatic diseases. In G. D. Hammer & S. J. McPhee (Eds.), Pathophysiology of disease: An introduction to clinical medicine (8th ed., Chapter 24). McGraw-Hill Education. AccessMedicine

Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. (2024). KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney International, 105(1S), S1–S69. https://doi.org/10.1016/j.kint.2023.09.002

Sammaritano, L. R., Askanase, A., Bermas, B. L., Dall’Era, M., Duarte-García, A., Hiraki, L. T., Rovin, B. H., Son, M. B. F., Alvarado, A., Aranow, C., Barnado, A., Broder, A., Brunner, H. I., Chowdhary, V., Contreras, G., Felix, C., Ferucci, E. D., Gibson, K. L., Hersh, A. O., . . . Mustafa, R. A. (2025). 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Care & Research, 77(9), 1045–1065. https://doi.org/10.1002/acr.25528

Sammaritano, L. R., Askanase, A., Bermas, B. L., Dall’Era, M., Duarte-García, A., Hiraki, L. T., Son, M. B. F., Werth, V. P., Aranow, C., Barnado, A., Broder, A., Brunner, H. I., Chong, B. F., Chowdhary, V. R., Hersh, A. O., Izmirly, P. M., Jules, M., Kalunian, K., Kamen, D., . . . Mustafa, R. A. (2026). 2025 American College of Rheumatology guideline for the treatment of systemic lupus erythematosus. Arthritis Care & Research, 78(7), 815–839. https://doi.org/10.1002/acr.25690